Company: SHPH
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0001493152-25-008300
Chunk: 7

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-26
Form: 10-K
Item: Item 1
Chunk 7
---
 novel, boron-containing PSMA ligand to enhance proton radiation therapy of prostate cancer, we discovered
PSMA-B, a molecule containing boron and demonstrating nanomolar binding activity to PSMA. Preclinical evaluations have been initiated
to explore the PSMA-B ligand as a potential prostate cancer sensitizer in combination with proton therapy, as well as a PET diagnostic
reagent and as a targeted prostate cancer therapeutic. By in-licensing our collaborator’s shares of the intellectual property,
Shuttle Pharma has an exclusive license to the PSMA-B intellectual property and has filed a patent application. Theranostic molecules
are suitable for diagnosis and therapy of cancers. The PSMA ligand is a molecule that binds to the PSMA, an enzyme that is highly expressed
in prostate cancer cells. The PSMA ligand is currently used for imaging and therapy to detect and treat prostate cancer.

    ●
    Develop
    PSMA-B as a potential diagnostic and therapeutic molecule in pre-clinical models in collaboration with academic nuclear medicine
    programs. Shuttle Pharma has licensed the intellectual property for the prostate cancer predictive biomarker test from inventors
    and will seek additional investment from NIH by applying for grant applications and from the public market to advance clinical pre-development
    through its Shuttle Diagnostics entity.

Our
Strategy

Our
goal is to maintain and build upon our leadership position in radiation sensitization. We plan to develop Ropidoxuridine and the HDAC6
inhibitor (SP-2-225) and, if approved by the FDA, commercialize our product candidates for the treatment of cancers. While this process
may require years to complete, we believe achieving this goal could result in new radiation sensitizer and immunotherapy products. Key
elements of our strategy include:

    ●
    Capitalize
    on Ropidoxuridine as an orally available, small molecule radiation sensitizer. To date, there is one drug (Cetuximab, a monoclonal
    antibody) approved by the FDA specifically as a radiation sensitizer. If we are successful in developing Ropidoxuridine and obtaining
    FDA approval, a small molecule sensitizer would then be enabled for clinical applications for radiation sensitization indications.

    ●
    Expand
    our leadership position within radiation sensitizers. In addition to our traditional radiation sensitizers, we plan to advance
    our near-term pipeline to include radiation sensitizers for proton therapy. Proton Therapy is growing